FDA approves lower dose of cabazitaxel in treatment of mCRPC

Yesterday, in line with previously reported data, the US Food and Drug Administration (FDA) approved the used of a 20 mg/ml dose of cabazitaxel (Jevtana) in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Differing chemotherapies and their effects in the treatment of mCRPC

The results of two recent, large clinical trials may have some impact on the clinical use of cabazitaxel (Jevtana) in the treatment of late-stage prostate cancer. … READ MORE …

NHS to stop covering cost of cabazitaxel for mCRPC as of November

As reported in a wide spectrum of media over the past few days (see here for example), on Friday last week the National Health Service announced that it would no longer cover the costs associated with use of cabazitaxel (Jevtana) in the treatment of metastatic, castration-resistant prostate cancer (mCRPC) through the UK’s Cancer Drugs Fund — effective as of November 1, 2015. … READ MORE …

Tasquinimod + cabazitaxel in heavily pre-treated men with mCRPC

According to media information from Active Biotech this morning, the company has initiated an early stage, combination therapy trial (the so-called CATCH trial) of their investigational agent tasquinimod + cabazitaxel (Jevtana®) for the treatment of men with heavily pre-treated, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Cabazitaxel gets final approval for marketing in Europe

According to a media release from Sanofi-Aventis, the European Commission has authorized marketing of cabazitaxel (Jevtana®) in all 27 countries of the European Union in combination with prednisone or prednisolone. … READ MORE …

European Medicines Agency approves cabazitaxel

According to a media release from Sanofi-Aventis and a report on the Reuters web site today, the European Medicines Agency (EMEA) has approved cabazitaxel (Jevtana) … READ MORE …

Report provides final results of the TROPIC trial of cabazitaxel

Cabazitaxel (Jevtana®) has recently been approved in the USA for the treatment of men with castration-resistant prostate cancer who have progressive disease following treatment with standard first-line chemotherapy (docetaxel + prednisone). … READ MORE …